超声造影诊断肝血管瘤及其预判肝动脉栓塞治疗的效果研究*

doi:10.3969/j.issn.1672-5069.2025.04.031

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (4): 601-604.doi: 10.3969/j.issn.1672-5069.2025.04.031

超声造影诊断肝血管瘤及其预判肝动脉栓塞治疗的效果研究^*

张聪, 张涛, 张骞

448000 湖北省荆门市人民医院超声诊断科(张聪,张骞);荆楚理工学院附属中心医院超声诊断科(张涛)

收稿日期:2025-02-11 出版日期:2025-07-10 发布日期:2025-07-14
通讯作者: 张骞,E-mail:zqa8b8@163.com
作者简介:张聪,男,38岁,大学本科,主治医师。E-mail:zcjm6400@163.com
基金资助:
^*湖北省荆门市科学技术研究与开发计划项目(编号:2022YFYB029)

Contrast-enhanced ultrasound in the diagnosis of hepatic hemangioma and in evaluation of efficacy after transcatheter arterial embolization

Zhang Cong, Zhang Tao, Zhang Qian

Department of Ultrasound, People's Hospital, Jingmen 448000, Hubei Province, China

Received:2025-02-11 Online:2025-07-10 Published:2025-07-14

摘要/Abstract

摘要： 目的分析肝血管瘤(HH)超声造影(CEUS)表现对疗效的影响。方法 2021年1月～2024年1月我院收治的HH患者86例,行常规超声和CEUS检查,接受经肝动脉栓塞(TAE)治疗。常规超声检查评估疗效。结果本组瘤体直径为5～10cm,平均为(7.4±1.1)cm;常规超声见HH病灶表现形态规则者65例(75.6%),边缘清晰者75例(87.2%),回声均匀者67例(77.9%),高回声者9例(10.5%),血供丰富者19例(22.1%);CEUS检查动脉期呈高增强38例(44.2%),呈整体增强33例(38.4%),呈向心性增强15例(17.4%),门静脉期呈离心性增强4例(4.7%),呈持续高增强46例(53.5%),呈等增强36例(41.9%),延迟期呈高增强3例(3.5%),呈等增强37例(43.0%),呈低增强46例(53.5%);在治疗3个月后,38例瘤体呈整体增强者TAE治疗有效率为73.7%%,显著高于48例呈向心性/离心性增强者的45.8%(P<0.05)。结论 TAE治疗HH患者效果好,而CEUS检查呈整体增强者可能更好。

关键词: 肝血管瘤, 超声造影, 经肝动脉栓塞, 诊断, 治疗

Abstract: Objective The aim of this study was to investigate contrast-enhanced ultrasound (CEUS) in the diagnosis of hepatic hemangioma (HH and in evaluation of efficacy after transcatheter arterial embolization (TAE). Methods 86 patients with HH were encountered in our hospital between January 2021 and January 2024, and all underwent routine ultrasonography (US) and CEUS. TAE was performed in all patients with HH, and efficacy was evaluated three months after. Results Diameter of HH in our series was 5-10cm, with average of (7.4±1.1)cm; routine US found HH lesion regular in 65 cases (75.6%), clean margins in75 cases (87.2%),homogeneous echo in 67 cases (77.9%),high echo in 9 cases (10.5%) and rich blood supply in 19 cases (22.1%);CEUS demonstrated lesions with arterial phase high enhancement in 38 cases (44.2%), with overall enhancement in 33 cases (38.4%) and with centripetal enhancement in 15 cases (17.4%), with portal phase centrifugal enhancement in 4 cases (4.7%), with continuous high enhancement in 46 cases (53.5%) and with equal enhancement in 36 cases (41.9%), and with delayed phase high enhancement in 3 cases (3.5%), equal enhancement in 37 cases (43.0%) and with low enhancement in 46 cases (53.5%); three months after TAE, complete and partial remission rate was found in 73.7%% in 38 patients with HH lesion of overall enhancement, much higher than 45.8%(P<0.05) in 48 patients with lesions of centripetal /centrifugal enhancement. Conclusion TAE is efficacious in treatment of patients with HH, and those with CEUS overall enhancement might be even more satisfactory.

Key words: Hepatic hemangioma, Contrast-enhanced ultrasound, Transcatheter arterial embolization, Diagnosis, Therapy

张聪, 张涛, 张骞. 超声造影诊断肝血管瘤及其预判肝动脉栓塞治疗的效果研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 601-604.

Zhang Cong, Zhang Tao, Zhang Qian. Contrast-enhanced ultrasound in the diagnosis of hepatic hemangioma and in evaluation of efficacy after transcatheter arterial embolization[J]. Journal of Practical Hepatology, 2025, 28(4): 601-604.

参考文献

[1] Zhou CM, Cao J, Chen SK, et al. Retrospective analysis based on a clinical grading system for patients withhepatic hemangioma: A single center experience. World J Gastrointest Surg, 2024, 16(7):2047-2053.
[2] 段海珊,蒋黎,田青青,等.原发性肝癌和肝血管瘤患者超声造影表现特点比较.实用肝脏病杂志,2023,26(3):420-423.
[3] Wu XF, Bai XM, Yang W, et al. Differentiation of atypical hepatic hemangioma from liver metastases: Diagnostic performance of a novel type of color contrast enhanced ultrasound. World J Gastroenterol, 2020, 26(9):960-972.
[4] Squires JH, Fetzer DT, Dillman JR. Practical contrast enhanced liver ultrasound. Radiol Clin North Am, 2022, 60(5):717-730.
[5] 田春燕,罗莉,曹雪玲,等.采用超声造影灌注及回声变化规律鉴别诊断肝血管瘤与肝细胞癌价值研究.实用肝脏病杂志,2024,27(4):603-606.
[6] 国际肝胆胰协会中国分会肝血管瘤专业委员会.肝血管瘤诊断和治疗多学科专家共识(2019年版).临床肝胆病杂志,2019,35(9):1928-1932.
[7] Shin YC, Cho EJ, Na HY, et al. Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate. Korean J Intern Med, 2023, 38(6):818-830.
[8] Jia K, Gao Z, Li M, et al. Interventional treatments for hepatic hemangioma: A state-of-the-art review. J Interv Med, 2022, 5(1):6-9.
[9] 魏野,汪施妤,葛高华,等.CT增强扫描与磁共振检查诊断肝血管瘤和肝细胞癌价值分析.实用肝脏病杂志,2024,27(2):279-282.
[10] Huang JX, Shi CG, Xu YF, et al. The benefit of contrast-enhanced ultrasound in biopsiesfor focal liver lesions: a retrospective study of 820 cases. Eur Radiol, 2022, 32(10):6830-6839.
[11] Cǎleanu CD, Sîrbu CL, Simion G. Deep neural architectures for contrast enhanced ultrasound (CEUS) focal liver lesions automated diagnosis. Sensors (Basel), 2021, 21(12):4126-4144.
[12] Ren L, Fei X, Zhu Y, et al. Ultrasound and contrast-enhanced ultrasound imaging in hepatic epithelioid hemangioendothelioma: a retrospective study of 13 patients. Med Ultrason, 2022, 24(4):414-420.
[13] 陈凯玲,张炜彬,毛枫,等.超声造影诊断炎症型肝细胞腺瘤的临床应用.中华超声影像学杂志,2021,30(1):48-53.
[14] Hakobyan K, Gaddam M, Ojinnaka U, et al. Contrast-enhanced ultrasound as a main radiological diagnostic method for primary liver neoplasms and hemangiomas. Cureus, 2021, 13(9):e18288.
[15] Panayiotou A, Rafailidis V, Deganello A, et al. Paediatric focal nodular hyperplasia: A case study of typical contrast-enhanced ultrasound findings with quantitative analysis and correlated with magnetic resonance imaging. Ultrasound, 2021, 29(2):128-134.
[16] Fang JQ, Ji YY, Zhao WA, et al. Three cases of hepatic epithelioid hemangioendothelioma evaluated using conventional and contrast-enhanced ultrasound: Case reports. J Clin Ultrasound, 2022, 50(6):826-831.
[17] Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol, 2020, 46(10):2579-2604.
[18] Yuan B, Zhang JL, Duan F, et al. Medium and long-term outcome of superselective transcatheter arterial embolization with lipiodol-bleomycin emulsion for giant hepatic hemangiomas: results in 241 patients. J Clin Med, 2022, 11(16):4762-4769.
[19] Kacała A, Dorochowicz M, Patrzałek D, et al. Safety and feasibility of transarterial bleomycin-lipiodol embolization in patients with giant hepatic hemangiomas. Medicina (Kaunas), 2023, 59(8):1358-1367.
[20] Küsbeci M, Elek A, Oztürk E, et al. Long-term outcomes of transarterial chemoembolization of giant liver hemangiomas with lipiodol-bleomycin emulsion. Cardiovasc Intervent Radiol, 2024, 47(11):1506-1514.

超声造影诊断肝血管瘤及其预判肝动脉栓塞治疗的效果研究^*

Contrast-enhanced ultrasound in the diagnosis of hepatic hemangioma and in evaluation of efficacy after transcatheter arterial embolization

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	呙冬慧, 陈婷, 茅明. 富马酸替诺福韦二吡呋酯联合当飞利肝宁胶囊治疗慢性乙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 509-512.
[2]	樊予惠, 黄素培, 侯爱敏, 王世英. 索磷布韦联合达诺瑞韦治疗基因3型初治的慢性丙型肝炎患者疗效和安全性分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 517-520.
[3]	林丽泉, 白晓苏, 张爱兰, 程小桂. 利托那韦增强的达诺瑞韦联合索磷布韦和利巴韦林方案治疗基因3型慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 521-524.
[4]	宋小宇, 陈宁, 高凤, 余仲苏. 儿童非嗜肝性病毒感染性肝损害患者病因与转归分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 525-528.
[5]	高倩, 陈璇, 周轶群, 杨欣, 康秀丽. 五脂胶囊联合复方甘草酸苷治疗非酒精性脂肪性肝炎患者疗效临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 529-532.
[6]	倪沈珏, 王鹏飞, 黄燕华, 曹利华. 非酒精性脂肪性肝病患者血清Maresin-1、网膜蛋白-1和微小RNA-125b水平变化及其与病情严重程度的关系研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 533-536.
[7]	唐晓路, 邓玲, 王金春, 沈美龙. 水飞蓟素联合甘草酸二铵治疗非酒精性脂肪性肝炎患者疗效临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 537-540.
[8]	王超智, 王珊, 田婉婷. 依折麦布联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 541-544.
[9]	张淑玮, 张惠娟, 周杰. 罗格列酮联合二甲双胍治疗非酒精性脂肪性肝病合并T2DM患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 545-548.
[10]	韩煜东, 张杰, 章文瑾, 何年安. 超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究[J]. 实用肝脏病杂志, 2025, 28(4): 553-556.
[11]	李莉, 朱文娟, 郭妮, 张彤, 杨亚峰, 赵芯. 泼尼松龙联合异甘草酸镁治疗自身免疫性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 561-564.
[12]	李晓静, 黄丽, 莫波, 沈才飞. 影响泼尼松治疗自身免疫性肝炎患者完全应答的多因素分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 565-568.
[13]	王燕燕, 周桐桐, 李娜, 卞兆连. PBC和PBC-AIH重叠综合征患者外周血树突状细胞及其亚群变化初步研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 569-572.
[14]	彭志芳, 吴莉, 盛秀红. 熊去氧胆酸治疗原发性胆汁性胆管炎患者血清MMP-1和IL-6水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 573-576.
[15]	施海群, 钱杰, 沈国倩, 赵萌. 索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者临床疗效和门脉超声检查指标变化研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 585-588.